VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2020 | Q-TWiST of lenvatinib + everolimus in advanced RCC

Chung Han-Lee, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York City, NY, discusses quality-adjusted time without symptoms or toxicity (Q-TWIST) analysis of patients enrolled in the HOPE-205 study (NCT01136733). Analysis suggests that the combination of lenvatinib plus everolimus in advanced renal cell carcinoma results in increased time without significant side effects when compared to everolimus monotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter